Biomaterial Database

[Treatment of prostatic carcinoma in an advanced stage. Our experience]. 1992

M Dublino, and F Lasaponara, and N Rizzello

Divisione Urologica, Ospedale G. Bosco, Torino.

The authors report the results of a retrospective study regarding 214 patients (mean age 73, smallest follow-up 6 months, greatest 70 months, average 42 months) affected by advanced prostatic cancer histologically demonstrated, observed from January 1983 to December 1990 and subject to hormonal treatment. They particular compared so-called "total androgenic suppression" (Gn-RH analogous or orchiectomy plus antiandrogen) with the "partial androgenic suppression" (Gn-RH analogous or orchiectomy). The authors report the results of the treatment regarding the subjective and the objective response, evaluated with NPCP criteria. Moreover the actuarial aspects of response and survival curves of two groups of patients are compared. The authors conclude that total compared to partial androgenic suppression does not offer significant advantages as regards to objective response and present their current treatment of advanced prostatic cancer.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009919	Orchiectomy	The surgical removal of one or both testicles.	Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011471	Prostatic Neoplasms	Tumors or cancer of the PROSTATE.	Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003131	Combined Modality Therapy	The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.	Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004054	Diethylstilbestrol	A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)	Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D005485	Flutamide	An antiandrogen with about the same potency as cyproterone in rodent and canine species.	Niftolid,Apimid,Apo-Flutamide,Chimax,Cytamid,Drogenil,Euflex,Eulexin,Eulexine,Fluken,Flulem,Flumid,Fluta 1A Pharma,Fluta-GRY,Fluta-cell,Flutamin,Flutandrona,Flutaplex,Flutexin,Fugerel,Grisetin,Niftolide,Novo-Flutamide,Oncosal,PMS-Flutamide,Prostacur,Prostica,Prostogenat,SCH-13521,Testotard,Apo Flutamide,ApoFlutamide,Fluta GRY,Fluta cell,FlutaGRY,Flutacell,Novo Flutamide,NovoFlutamide,PMS Flutamide,SCH 13521,SCH13521
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000206	Actuarial Analysis	The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.	Analysis, Actuarial,Actuarial Analyses,Analyses, Actuarial
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly

Related Publications

M Dublino, and F Lasaponara, and N Rizzello

[Treatment of advanced prostatic carcinoma with ketoconazole. Our experience in 10 cases].

January 1989, Actas urologicas espanolas,

M Dublino, and F Lasaponara, and N Rizzello

[Personal experience with treatment of advanced prostatic carcinoma using Estracyt].

November 1987, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti,

M Dublino, and F Lasaponara, and N Rizzello

[Prostatic prosthesis in the treatment of prostatic hypertrophy: our experience].

February 1995, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica,

M Dublino, and F Lasaponara, and N Rizzello

Treatment of advanced prostatic carcinoma.

September 1979, British medical journal,

M Dublino, and F Lasaponara, and N Rizzello

[Therapy of advanced prostatic carcinoma: personal experience].

March 1992, Archivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell'Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences,

M Dublino, and F Lasaponara, and N Rizzello

Effect of previous treatment on Estracyt response in advanced stage D prostatic carcinoma.

June 1984, Urology,

M Dublino, and F Lasaponara, and N Rizzello

Treatment of locally advanced prostatic carcinoma.

November 1976, The British journal of radiology,

M Dublino, and F Lasaponara, and N Rizzello

[Treatment of advanced metastasizing prostatic carcinoma].

June 1972, Das Deutsche Gesundheitswesen,

M Dublino, and F Lasaponara, and N Rizzello

[Treatment of advanced prostatic carcinoma using estramustinphosphate].

January 1983, Actas urologicas espanolas,